Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Journal of Hematology & Oncology|November 29, 2022
Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TCLudovic Jondreville, Maud D'Aveni, Hélène Labussière-Wallet, et al.
Haematologica|April 17, 2025
A phase II study of ponatinib for prevention of relapse after allotransplantation in <i>FLT3</i> internal tandem duplication mutation positive (FLT3-ITD+) acute myeloid leukemia: the PONALLO trialPatrice Chevallier, Anne Thiebaut, Sylvie François, et al.
Oncotarget|December 20, 2018
Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TCAmandine Le Bourgeois, Myriam Labopin, Mathieu Leclerc, et al.
Oncotarget|October 17, 2018
Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignanciesPatrice Chevallier, Pierre Peterlin, Alice Garnier, et al.
Ejhaem|March 22, 2022
Anti-SARS-CoV-2 vaccines in recipient and/or donor before allotransplantMaxime Jullien, Marianne Coste-Burel, Beatrice Clemenceau, et al.
European Journal of Haematology|January 11, 2013
Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT)Amandine Le Bourgeois, Elsa Lestang, Thierry Guillaume, et al.
Annals of Hematology|March 16, 2019
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective studySabrina Trudel, Benoît Tessoulin, Maxime Jullien, et al.
British Journal of Haematology|November 9, 2018
A novel complete blood count-based score to screen for myelodysplastic syndrome in cytopenic patientsRobin Boutault, Pierre Peterlin, Marouane Boubaya, et al.
Annals of Hematology|April 29, 2020
Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamideAlice Garnier, Thierry Guillaume, Pierre Peterlin, et al.
Annals of Hematology|May 18, 2020
Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real lifeClara Sortais, Anne Lok, Benoit Tessoulin, et al.
Pageof 7